Overview

This event will showcase the role the clinical scientist plays in translating innovations into the clinic. Internationally leading academics will present leading examples of emerging and postulated technologies and discuss how they can revolutionise healthcare. Leading clinical scientists will present on current and emerging innovations in the use of novel technology in healthcare. The event will provide opportunities for networking and open discussion to direct future interdisciplinary research and technology development.

The UK has always been at the forefront of scientific excellence. From the discovery of antibiotics, the development of the laser scanning confocal microscope, to our world-leading 100,000 Genomes project, we have a proud history of medical breakthrough and innovation.

By giving staff brand new innovations and technology to work with, or being at the heart of research to innovate and develop new technology clinical scientists are able to quickly translate and share advances across the health and social care system and directly contribute to patient outcome. The UK has strong and growing life sciences sector which translates physical science advances into patient focused technologies. Within this sector:

  • The Rosalind Franklin Institute is a new national institute, funded by the UK government through UK Research and Innovation, dedicated to bringing about transformative changes in life science through interdisciplinary research and technology development.
     
  • The United Kingdom Life Sciences Industrial Strategy also contributes £14 million funding to support 11 medical technology research centres to encourage collaboration between the NHS and industry in developing and bringing new technologies to patients through the National Institute for Health Research (NIHR). 

The aim, that patients will continue to benefit from new technologies which will help to improve diagnosis and get them the treatment they need quickly. 
 

 

Programme

08:30    Registration and refreshments
09:00    Welcome and Introduction 
09:10    Healthcare Science driving Innovation - Professor Sue Hill, London 
10:00    Role of Technology and improving early diagnosis - Sir John Bell, Oxford 
10:50    Questions
11:10    Refreshments 
11:30    Clinical potential for large volume Electron Microscopy - Lucy Collinson, London
12:00    Genomics - Professor Sian Ellard, Exeter 
12:30    Questions 
12:50    Lunch 
13:40    Gene Therapy - Professor Matthew Wood, Oxford 
14:10    Mass spectrometry – Professor Zoltan Takats, London 
14:40    Questions 
15:00    Refreshments 
15:20    Artificial Intelligence – Professor Sebastien Ourselin, London
15:50    Topic - TBC
16:20    Questions 
16:40    Roundtable discussion – Including all speakers of the event
17:10    Close

Registration

Online rates

Members £202.00
Concessional £108.00 - Includes trainees, BMS, non-consultant Clinical Scientists, retired & nurses
Non-members £280.00

Offline rates (payments via cheque/invoice or on the day payments)
Members £238.00
Concessions £142.00 - Includes trainees, BMS, non-consultant Clinical Scientists, retired & nurses
Non-members £312.00

Please note that an administrative charge of £20.00 will be made on all cancellations and the total registration fee is forfeited if cancelled one working week before the event.

Location

To be held at the Royal College of Pathologists, 6 Alie Street, London E1 8QT.

Speakers

Clinical Science workshop

  • Professor Sir John Bell

    Professor Sir John Bell GBE, FRS is Regius Professor of Medicine at Oxford University.  He served as President of the Academy of Medical Sciences from 2006 to 2011 and chaired the Office for the Strategic Coordination of Health Research until 2017.  As a Rhodes Scholar (1975-78), Sir John undertook his medical training in the UK and then went on to Stanford University, returning to the UK in 1987.  His research interests are in the area of autoimmune disease and immunology where he has contributed to the understanding of immune activation in a range of autoimmune diseases.  In 1993, he founded the Wellcome Trust Centre for Human Genetics, one of the world’s leading centres for complex trait common disease genetics.  In 2001, he was appointed non-executive director of Roche Holding AG and in 2008 he joined the Gates Foundation Global Health Advisory Board which he has chaired since 2012.  He is Chair of the Rhodes Trust.  In December 2011, Sir John was appointed one of two UK Life Sciences Champions by the Prime Minister.  He sits on the board of Genomics England Limited and chairs its Science Advisory Committee.  He was appointed Knight Grand Cross of the Order of the British Empire (GBE) in the 2015 New Year Honours for services to medicine, medical research and the life science industry. In August 2017, the UK Life Sciences Industrial Strategy, written by Sir John, was published.  The report, written in collaboration with industry, academia, charity, and research organisations, provides recommendations to HM Government on the long-term success of the life sciences sector.

  • Professor Matthew Wood

    MATTHEW WOOD is Professor of Neuroscience and Deputy Head of the Medical Sciences Division at the University of Oxford. He directs the Laboratory of RNA biology and Neuromuscular Disease investigating development of RNA-based medicines for neuromuscular disease focusing on the development of advanced generation antisense oligonucleotides for Duchenne muscular dystrophy and related neuromuscular conditions. He is currently Director of MDUK Oxford Neuromuscular Centre and Director of the Oxford Harrington Rare Disease Centre. His research team will form a core component of a new Oxford-based institute known as the Institute for Developmental and Regenerative Medicine (IDRM). He has pioneered the development of novel drug delivery systems including peptide and exosome-based technologies for the targeted delivery of macromolecular biologics, including oligonucleotides, to tissues including the brain. He is a co-founder of the biotech spin-outs Evox Therapeutics (developing therapeutic exosome technology) and PepGen (developing peptide based drug delivery technology), and has recently led a major UK national initiative to establish a UK Nucleic Acid Therapy Accelerator (NATA). Matthew is or has been an advisor to numerous research funding agencies including the UK Medical Research Council and Wellcome Trust. In his role as Deputy Head of the Medical Sciences Division of the University of Oxford, Matthew leads strategic coordination of all innovation related activities. He currently serves as a Non-Executive Director of the University of Oxford’s technology transfer organization, Oxford University Innovation (OUI).

  • Dr Lucy Collinson

    Dr Lucy Collinson is an electron microscopist with a background in microbiology and cell biology. She has a degree and PhD in Medical Microbiology, and post-doctoral research investigating membrane trafficking pathways. She has run a series of biological EM facilities since 2004, at UCL and then at the Cancer Research UK London Research Institute, which became part of the new Francis Crick Institute in 2015. With a team of 10 electron microscopists and 3 physicists, she oversees more than 100 research projects with more than 60 research groups within the Crick, imaging across scales from proteins to whole organisms.